The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Great to watch and just reinforces why AVO and LIGHT must succeed, the Christie Foundation Hospital highlighted while pioneering and successful required a significant larger footprint and much more shielding than AVO’s LIGHT. The Linac design of LIGHT generates lower levels of secondary radiation compared to cyclotron systems such as the Christie reducing the need for extensive shielding and therefore huge cost savings . As we know AVO’s LIGHT is designed therefore to be located in inner city areas occupying as planned within the basement area of 141-143 Harley Street which has just 15,000 sqft area in total.
AVO with CERN are clearly pioneers of the next generation of disruptive technology with LIGHT making proton beam therapy more accessible and cheaper for future generations and builds on their success with traditional cyclotron systems. Hospitals like the Christie will continue to play a major part and hopefully with AVO & CERN more proton beam therapy centres will be affordable and accessible to a wider population.
Https://citywire.com/new-model-adviser/news/wh-ireland-seeks-5m-to-avert-collapse-after-fca-talks/a2422668
Interesting development as they are handling any potential Nasdaq potential partners
I would hope we hear some developments next week regarding the consolidation, sub division and financing as everyday that passes is costing a great deal to those covering any bridging loan
IWTO that is a possibility however that would make the total number of shares even more totally “unwieldy” in the words of the directors. It is the only comment I find personally the most revealing, for that reason I expect as we move forward total shares issued will be less than today just depends how much.
With support from perhaps another major investor / current investors I believe all realise at this 11th hour and technically de risked position the shares are worth much more than the current market cap. Time will tell and I expect to hear a concrete plan by the end of July. GLA
I have been thinking about this Share consolidation and it is interesting with AVO's proposal that it will be followed by a subdivision/Share Split: being the opposite of a share consolidation, increasing the number of outstanding shares while proportionately decreasing the share price, usually done to make the shares more affordable and increase market liquidity. Which is clearly the only reason to move forward on this basis as no new issues will be issued at the prevailing nominal value of 25 pence.
As I understand the purpose of using both share consolidation and share split together would be to also sort out any convertible securities and adjust the nominal value of the shares simultaneously. Therefore by consolidating the shares first, the company can convert the convertibles on a consolidated basis, ensuring a more accurate conversion ratio. Then, through the subsequent share split, the nominal value of the shares can be reduced.
So hypothetically how could this work especially seeing the comment AVO make about the number of current shares?
“The Directors consider that the number of existing Ordinary Shares is not only unwieldly in volume for a company of Advanced Oncotherapy's market capitalisation, but when combined with the prevailing share price, is not conducive to an orderly market”.
So lets say they consolidate 10:1 and then assume a share split 1:2
If they are going to raise lets say the lower amount of £61.7 Million are they really going to be able to issue new shares lower than 20p??? they will still end up with 417 million shares versus now 542,573,869
Possible Equity Issue Price: 20 pence
Number of New Shares Required:
Total Equity Fundraising Amount / Issue Price for £61,700,000 @ 0.20 = 308,500,000 shares
Share Consolidation and Subdivisionn
Share Consolidation:
Assuming a consolidation ratio of 10:1, : (Even at 20:1 does not make a huge difference to overall sharevolume)
542,573,869 shares / 10 = 54,257,387 shares
Subdivision/Share Split:
Assuming a 1:2 share split, :
54,257,387 shares x 2 = 108,514,774 shares
To achieve the equity fundraising goal of £61.7 million, the company would have:
308,500,000 + 108,514,774 = 417,014.774 Issued shares
This is all hypothetical but I guess my point is focusing on the 'unwieldly' volume of shares and therefore perhaps unlikely to see an offer price any lower, which for all shareholders is very good news. If through this combined action they can also take out Odey the share price could do very well combining a capital raise which should be suffcient to totally complete all certfication and finally treating customers.
All thoughts welcomed, at the end of the day I just want the company to succeed, both as a shareholder and for the good of mankind.
Over £200 million as far as I am aware
Final results due this week, please BOD give some meaningful updates, shareholders should have an update on both Nasdaq discussions and an operational update especially certification and treating first patient definitive date. No regular updates at this time are destroying shareholder value. I hope we get some announcements and new additions to the board and investment announcements to turn this company around ASAP and enable the company to meet and complete their operational objectives.
Interesting indeed 1.8 million shares bought at 5p in a combination of large purchases in a little over half an hour. Hoping for positive funding news this week.
Interesting times, non dilutive options could of course involve a Nasdaq Listing company partnering with the company and injecting cash, I would be extremely surprised if serious discussions are not currently in play since the April announcement especially as the company has always been fully engaged in the USA and particularly with the Cleveland Clinic one of the companies highly respected world renowned research partners. I am also encouraged new participants are buying shares and joining the Loan note holders, as insiders they will have an uptodate perspective of how discussions are going.
The company continues to receive the support of some seriously wealthy LT shareholders and institutional investors who have not sold and who I guess if push came to shove at this 11th hour prior to treating first patients would also continue to support further, if I was them I would of course prefer all other options are first prioritised.
We must not forget also that this tech is proven, well protected by AVO patents and it will be disruptive in the market place. Competitors and major suppliers will be watching and perhaps even wishing to partner with the company.
Hoping for some positive indications of discussions this month.
I have been encouraged to see the major shareholders and a number of large new shareholders coming on board buying stock and supporting the convertible loan notes these past few weeks. The partcipation also by the board shows significant confidence. IMO positive progress will be forthcoming sooner probably than many expect and the shares should then re rate significantly to the upside, clearly AIM is just not the right market for this company which is still on track to treat new patients in H2 year having achieved all major hurdles not least achieving 230 MeV. The capital investment made by the company todate and progress in terms of expected delivery in H2 2023 defy any logic in my mind as to the current share price. While I am sad to see where the price is today after all the great work achieved by the BOD, I am also fortunate to have built a sizeable position. I am hoping to hear sooner rather than later progress on Nasqaq parties interested, a further Operations Update and progress with sales pipeline contractual negotiations. GLA, while these are challenging times I am excited by the oppotunities ahead for the company.
I do not believe they will be out of funds, reading between the lines it seems both directors and major shareholders will continue to support the company as they progress a number of avenues that will most benefit shareholders. Clearly DCNA seem to have thrown in the towel for one reason or other but unless we get another announcement no other major shareholder representing I guess around c 50% of the total shareholders has sold. The overhang alone on DCNA at some point will be cleared, IMO also the company will be of significant interest to some major players and as such this could prove to be a good entry point for them based on the £200 million so far invested in the technology which is on course to treat first patients H2 2023 and has achieved 230 MeV. There is always a risk but I have been buying. Good luck AVO and all shareholders.
It always surprises me the reacion of markets. The Annual Results were the best I have seen for some years with this company and the optimistc outlook augers well for the future. I liked this section:
"we are now more hopeful that the royalty income
will experience exponential growth from 2023 and beyond. Regarding SenstendTM in
China, we are working hard with our commercial partner Wanbang Biopharmaceutical
who are aiming to submit the NDA to NMPA in Q3 2023. And the same goes for the
US, where we continue to advance our NDA and more importantly have an agreed
roadmap with the FDA for its submission. Both these NDAs if approved will be game
changers for the Group.
We are excited about DLI with the launch of SenoClock@ in late 2022 as it has
managed to sign its first customers and will importantly expand its product offering in
2023, with introduction of MindAge@ to its SaaS@ platform."
Honestly I am not surpised by this collapse in the shareprice, investor confidence has gone, so many missed targets. I am pleased I sold out most of my holding at 36p and regret holding what I have left. The company should spend more time keeping investors up to date with progress following achieving 230 MEV, for example number of contractual discussions and more frequent news regarding progress with licensing. There have been to many generic news releases regarding the advantages of LIGHT which is simply not relevant until such time AVO has a fully licensed and operating system. I feel there are some industry insiders that probably know more of what is happening with the licensing schedule and maybe they are selling. Shares at an all time low for whatever the reason signifies to me that the BOD are simply not communicating as much as they should. Plus there are many investors that have been squeezed put by multiple fund raising at artificially high share prices backed by warrants. I like to think that this is still a £1 to £2 share but I fear a takeover or inability to raise sufficient capital going forward without real progress is going to limit any further progress. Ever hopefull
It will be interesting to read the Interim Results for further progress which are likely to be released tomorrow. Unfortunatley the share price responding very poorly following achieving 230 MeV is a symptom of the current market turbulence and also I suspect investors disapointment in past milestones just not being achieved, it takes a great deal of time to build investor confidence and it would appear that confidence over the past year has erroded. There just appears too many hurdles ahead before first patient treatment is achieved H2 2023, more progress on all the approvals and certfication I hope will be revealed soon and I contiune to wish the company and BOD well in bring this disruptive and amazing technology to fruition.
At last very good to hear and first patient treatment H2 2023.
I expect to hear contracts being secured going forward now and the share price be re rated.
Good job BOD pleased you made this milestone
I sincerely hope that the interim results announcement due this week is not a further delay announcement. Investor confidence now requires a good interim report for the shares to fly including that they can now meet the objectives of securing 230MeV. The end of the Summer is now so I am hoping there is not another let down. I am not very confident.
Thanks for your reply, we are in agreement. What I find most annoying are releases generally about LIGHT technology in the wider market and while this is interesting often it is old news re packaged. Until we have a working LIGHT system thats able to fulfil its market and current sales obligation I am just not at all interested in scientific reports concerning LIGHT, all I want to know is that we have a fully operating and approved system, if it is before the end of August great I will be an even longer term holder. 29th July AGM seems to be an extremely relevant date to announce significant milestones being at last achieved. No more delays please
As a significant holder I am probaly like many here frustrated with the constant delays the company has had over the last 2 years while understanding the challenges with Covid, micro chips etc. However if i have read all the updates correctly we now have all CCL's and technology completed and the company is increasing the Mev to 240 alongside testing and validation which I beleieve they have advised will be all completed by the end of the summer. In that I would understand by the end of August. Personally if there is a nother delay I will be selling as I am courting a number of other opportunities. I will be interested to know others views.
I am afraid I see this small in house buying as a way of trying to prop up the price in these very uncertain times. Personally i have hugely reduced my holdings having used the funds to make 100-300% on commodities. I like the company and will top up nearer to mid year but for now these continual delays do not help shareholders. When the compamy can announce first test and 230mv it will be greast news.
Seriously this company is becoming a joke, I sincerely hope we get some meaningful news and not promises of how technology in this spaces is revolutionary. It is about time the company produced actual progress themselves, news on the MeV speed, specific target launch date treating first patients, commercial contracts, news on Harley Street which seems to imply no progress there at all dispite all the previous news regarding a tie up with The London Clinic, regretably the share price says it all. As a large shareholder it would be great at this stage if a takeover offer is made but unfortunately the company have not proved themselves and have consistently pushed the timeline out without hitting previous milestones. No longer can the company hide behind Covid restrictions. Please provide definitive progress and a more specific time table to launch. If we can see some action then hopefully we will begin to get closer to the inflated target share prices publicised by their in house broker.
I am afraid watching the lack of progress with AVO is worse than watching paint dry. Really I wish the company would announce some meaningful progress on MeV speed achievements and more details on how the LIGHT system is progressing. I have been a keen holder for a number of years and truly believe in the tech just disappointed with the companies communication. Whenever there is a release its all about jam tomorrow in terms of the potential of LIGHT. We do need more factual information in terms of the timeline and hopefully more confirmed contracts. News is often followed by a significant CR and then we are back to square one. Frustrating as it is I wish the company well but as LT shareholders I would appreciate more detail and more precise timelines, we must be due another technical update, hoping for some surprises.